Supplemental Application for Avatrombopag in ITP Accepted by FDA
November 9th 2018A supplemental new drug application (sNDA) for avatrombopag (Doptelet) as a treatment for patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to prior treatment has been accepted for review by the FDA.